A total of 332 patients with stage III/IV disease harboring EGFR mutations without an indication for radical radiotherapy or surgery or with EGFR-mutant recurrent NSCLC were consecutively enrolled in this registry study from July 2017 to September 2020 (Fig. 1). Here, EGFR is linked to non-small cell lung carcinoma.